

## UPDATE FOR THE AMYLOIDOSIS COMMUNITY

BridgeBio has announced that the ATTRibute-CM trial, a Phase 3 study for ATTR-CM, achieved its primary endpoint.

BridgeBio Pharma is a biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients with genetic diseases and cancers with clear genetic drivers. Together with Eidos Therapeutics, we are developing an investigational, orally-administered small molecule designed to potentially stabilize tetrameric transthyretin (TTR) by mimicking the structure of the T119M TTR variant. This naturally-occurring variant is known to protect carriers from developing ATTR.

BridgeBio plans to file a New Drug Application (NDA) with the US FDA by the end of 2023. This means BridgeBio will submit data from the investigational study to regulators, who will decide whether to approve the drug to be marketed in the US.

Acoramidis is an investigational drug. The safety and efficacy of acoramidis have not been established. There is no guarantee that acoramidis will receive health authority approval or become commercially available in any country in which it is being investigated.



### Upcoming Presentations

#### European Society of Cardiology

Data from the ATTRibute-CM phase 3 trial will be presented at the European Society of Cardiology conference in August 2023.



### Further Information

For more information about acoramidis, please contact BridgeBio Medical Information at [medinfo@bridgebio.com](mailto:medinfo@bridgebio.com).

We are incredibly grateful to the over 600 individuals who have participated in the clinical research process to determine the safety and efficacy of acoramidis. You and your families have been crucial in contributing to ongoing research into amyloidosis.